Further, it might be a valuable option for refined prognostic assessment in patients with IDH-wt GBM and an age ≥ 55 years where genetic testing is currently regarded as not-necessary according to recommendations of the WHO classification [47]. This evidence concerns the gene IDH1 and glioblastoma.